CO - Global Cord Blood: With 6.0x P/E And 24% EPS CAGR Subscriber Growth Continues
- Revenues increased 10% this quarter.
- The company grew in subscribers count this quarter and this was a positive sign.
- 24% EPS 5-year CAGR, which points to the company’s ability to maintain secular growth.
- 203% net cash to the market cap.
- 6.0x P/E makes CO very undervalued.
For further details see:
Global Cord Blood: With 6.0x P/E And 24% EPS CAGR, Subscriber Growth Continues